A Phase 1b study of anti-cancer drug WXUK1 in patients with advanced solid tumours.
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2017
At a glance
- Drugs WX UK1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Heidelberg Pharma AG; WILEX AG
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 02 Aug 2006 New trial record.